Lefty inhibitors belong to a distinct class of chemical compounds known for their pivotal role in regulating embryonic development and cell differentiation. These inhibitors are closely associated with the transforming growth factor-beta (TGF-β) superfamily of signaling molecules. To understand Lefty inhibitors, it's essential to appreciate their role within the intricate process of embryogenesis. During early development, Lefty inhibitors play a fundamental role in establishing the body plan of an organism. They are known for their function in maintaining symmetry and axis formation, a critical step in the early stages of embryonic development. Lefty inhibitors act as antagonists to certain signaling pathways within the TGF-β superfamily, exerting their influence by interfering with the signaling molecules involved. Specifically, they counteract the activity of Nodal, an important TGF-β member, which plays a key role in specifying the left-right axis in vertebrates. By doing so, Lefty inhibitors help ensure that the developing embryo forms with appropriate bilateral symmetry, preventing developmental abnormalities and ensuring the proper organization of vital organs.
Lefty inhibitors can be broadly classified into two isoforms: Lefty-1 and Lefty-2. Both isoforms exhibit similar mechanisms of action, working as negative regulators by binding to Nodal and inhibiting its signaling. This function is crucial for maintaining the balance of the Nodal pathway, preventing excessive or inappropriate signaling that could lead to developmental defects. Lefty inhibitors are a prime example of the delicate checks and balances that govern embryonic development. Their presence ensures the precise orchestration of signaling pathways, guaranteeing that an organism's body plan and symmetry are established correctly during its early stages of development. Understanding the mechanisms of Lefty inhibitors is not only essential for developmental biology but also holds potential implications for various fields of science and medicine, shedding light on the intricacies of cell signaling and differentiation.
Items 11 to 15 of 15 total
展示:
产品名称 | CAS # | 产品编号 | 数量 | 价格 | 应用 | 排名 |
---|---|---|---|---|---|---|
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | ¥4648.00 | 32 | |
拉帕替尼是表皮生长因子受体和 HER2 的双重抑制剂,可抑制酪氨酸激酶,阻碍 HER2 阳性乳腺细胞的生长和扩散。 | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | ¥1297.00 ¥4682.00 | 11 | |
维莫非尼(Vemurafenib)可特异性抑制 BRAF V600E 基因突变,阻止带有这种特定突变的黑色素瘤细胞失控增殖。 | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | ¥3610.00 ¥4851.00 | 3 | |
瑞戈非尼是一种针对血管生成受体、基质激酶和致癌激酶的多激酶抑制剂,有助于控制生长和血管生成。 | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | ¥970.00 | ||
奥希替尼是一种表皮生长因子受体酪氨酸激酶抑制剂,旨在靶向表皮生长因子受体T790M突变,克服非小细胞肺癌(NSCLC)患者的耐药性。 | ||||||
5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine | 1032900-25-6 | sc-505041 | 1 mg | ¥2595.00 | ||
Ceritinib 可抑制 ALK 和 ROS1 激酶,专门用于研究 ALK 或 ROS1 基因重排的非小细胞(NSCLC),阻止肿瘤生长。 |